Cheyne Capital Management (UK)’s KalVista Pharmaceuticals KALV Stock Holding History

Cheyne Capital Management (UK)’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-52,790	Closed	-$357K	–	36
2022 Q4	$357K	Buy	+52,790	New	+$283K	0.62%	43

Other funds holding KALV

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Cheyne Capital Management (UK)'s KALV Position: Q1 2023 in Review

Cheyne Capital Management (UK) sold out of KalVista Pharmaceuticals (KALV) in Q1 2023, closing a stake of 52,790 shares — an estimated $357K sold.

Cheyne Capital Management (UK) first reported a position in KALV in Q4 2022 and held it in 1 quarter. The position peaked at $357K in Q4 2022. 88 funds tracked by Wall St. Rank hold KALV as of Q1 2023.

Cheyne Capital Management (UK) reported no remaining KalVista Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Cheyne Capital Management (UK) sold 52,790 KalVista Pharmaceuticals shares in Q1 2023, an estimated $357K.
Cheyne Capital Management (UK) first reported a position in KalVista Pharmaceuticals in Q4 2022 and held it in 1 quarter.
Cheyne Capital Management (UK)'s KalVista Pharmaceuticals position peaked at $357K in Q4 2022.
88 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2023.

Based on Cheyne Capital Management (UK)'s 13F filing for Q1 2023, filed 3 May 2023.